• In recent weeks, Energy Transfer LP raised its full-year 2026 adjusted EBITDA and organic growth capital guidance following strong first-quarter results, while several major banks reaffirmed positive ratings and outlooks on the partnership.
• Investor attention has also been fueled by high-profile endorsements and inclusion in “top oil and gas stocks” lists, underscoring how sentiment around Energy Transfer’s diversified midstream footprint is evolving.
• Next, we’ll examine how Energy Transfer’s upgraded 2026 EBITDA guidance could reshape its existing investment narrative and assumptions around future growth.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.

Energy Transfer Investment Narrative Recap

To own Energy Transfer, you need to believe its diversified midstream network and large organic project pipeline will convert higher forecast 2026 EBITDA into durable cash flows, despite volume, execution and regulatory risks. The upgraded 2026 guidance and recent analyst support strengthen the near term earnings and capital allocation story, but they do not fully resolve concerns around project timing, cost discipline or exposure to still-evolving demand from power, LNG and data center customers.

The most relevant development here is Energy Transfer’s higher 2026 adjusted EBITDA and organic growth capital guidance, coming alongside solid first quarter results and supportive commentary on its diversified asset base. This directly ties into the core catalyst of large new natural gas and NGL projects, while also putting a brighter spotlight on the risk that any permitting delays, cost overruns or weaker than expected volumes could leave those higher targets harder to achieve.

Yet against this stronger outlook, investors should still be aware of how heavily future returns depend on large, long lead time projects that...

Energy Transfer's narrative projects $116.5 billion revenue and $6.2 billion earnings by 2029. This requires 8.1% yearly revenue growth and a $2.1 billion earnings increase from $4.1 billion.

Uncover how Energy Transfer's forecasts yield a $23.50 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members’ fair value estimates for Energy Transfer range from US$16.23 to US$45.52 across 11 independent views, underscoring how far opinions can differ. Some focus on the upgraded 2026 EBITDA guidance and expanding project backlog, while others emphasize that execution and regulatory risks on multi billion dollar pipelines could materially influence future performance and invite a closer look at differing assumptions.

Explore 11 other fair value estimates on Energy Transfer - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Energy Transfer research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Energy Transfer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Energy Transfer's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.